The following information appeared on, cms.gov
On February 24, the FDA revised the emergency use authorization for tixagevimab co-packaged with cilgavimab (EVUSHELD™) to change the initial dose for the authorized use as preexposure prophylaxis of COVID-19 in certain adults and pediatric patients.
